PYC Therapeutics Limited (ASX: PYC) - ETF Exposure

Current share price for PYC : $2.225 0.035 (1.55%)⁺

PYC Therapeutics (PYC) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class.

PYC General Information ⁺

ASX Code	PYC
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	2,188
PYC Share Price	$2.225
Day High	$2.310
Day Low	$2.200
Last Close	$2.260
PYC Share Price Movement	$0.03 ( 1.55% )

Prices as at 11:50, 28 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to PYC

As a significant Australian company by market capitalisation, PYC is held across 3 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when PYC moves, funds like VSO, A300 and VAS that hold it can move with it.

For more concentrated exposure, ETFs such as VSO (Vanguard MSCI Australian Small Companies Index ETF) allocate about 0.2% to PYC , while the average exposure across all 3 ETFs that hold it is around 0.1% .

Top ETF holdings

Vanguard MSCI Australian Small Companies Index ETF (VSO) ~ 0.2%
Global X Australia 300 ETF (A300) ~ 0%
Vanguard Australian Shares Index ETF (VAS) ~ 0%

Last updated: ETF data and holdings as at 27 August 2026

Own PYC directly or through an ETF?

How does holding PYC Therapeutics Limited (PYC) shares directly compare to ETFs that include it?

	PYC Direct	VSO ASX	A300 ASX	VAS ASX
Holdings	1 company	194 holdings	298 holdings	318 holdings
PYC Weight	100%	0.2%	0%	0%
Diversification	Single Stock	Broad	Broad	Broad
Annual Cost	Brokerage only	0.3% p.a.	0.03% p.a.	0.07% p.a.
Approx. Yield	-	4.62%	2.94%	2.88%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not PYC's direct yield. Annual cost uses each ETF's MER.

PYC Exposure on $10,000 investment

How a $10,000 investment in PYC Therapeutics Limited (PYC) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
PYC Therapeutics Limited (PYC)	Direct share	$2.225	1.14%	+$114	$10,114
Vanguard MSCI Australian Small Companies Index ETF (VSO)	Equity - Australia Small/Mid Cap	$75.660	0.27%	+$27	$10,027
Global X Australia 300 ETF (A300)	Equity - Australia	$52.800	0.02%	+$2	$10,002
Vanguard Australian Shares Index ETF (VAS)	Equity - Australia	$112.840	-0.03%	-$3	$9,997

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

PYC Therapeutics Limited (PYC) ETFs

3 ETFs hold PYC Therapeutics Limited (PYC).

ETF	PYC Weight	MER	Yield
Vanguard MSCI Australian Small Companies Index ETF (VSO)	0.2%	0.3%	4.62%
Global X Australia 300 ETF (A300)	0%	0.03%	2.94%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	2.88%

PYC Therapeutics Limited (PYC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from PYC Therapeutics Limited (PYC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

PYC Therapeutics Limited (PYC) price-sensitive announcements

PYC - Quarterly Activities/Appendix 4C Cash Flow Report

PYC Therapeutics Limited, a clinical-stage biotechnology company based in Australia, relea

PYC Therapeutics Limited (PYC)
29 Jul 2026 | 8:45 AM

PYC - PKD - Safety Committee Approves Dose Escalation

PYC Therapeutics Limited, a precision medicine company, announced that the Safety Review C

PYC Therapeutics Limited (PYC)
22 Jul 2026 | 8:20 AM

PYC - ADOA Program Update

PYC Therapeutics Limited, an Australian precision medicine company, announced significant

PYC Therapeutics Limited (PYC)
21 Jul 2026 | 8:32 AM

PYC - PKD - Initiation of Multiple Dose Clinical Trial

PYC Therapeutics Limited has initiated a Phase 1b Multiple Ascending Dose (MAD) clinical t

PYC Therapeutics Limited (PYC)
7 May 2026 | 9:03 AM

PYC Therapeutics Limited (PYC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	Notification regarding unquoted securities - PYC	26 Aug 2026 4:54PM	$2.170	$2.225	risen by 2.53%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	Investor Webinar	18 Aug 2026 8:16AM	$2.130	$2.225	risen by 4.46%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	Change of Director's Interest Notice	14 Aug 2026 11:02AM	$2.130	$2.225	risen by 4.46%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	Notification regarding unquoted securities - PYC	13 Aug 2026 2:42PM	$2.110	$2.225	risen by 5.45%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	Quarterly Activities/Appendix 4C Cash Flow Report	29 Jul 2026 8:45AM	$1.625	$2.225	risen by 36.92%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$2,188	PKD - Safety Committee Approves Dose Escalation	22 Jul 2026 8:20AM	$1.625	$2.225	risen by 36.92%

PYC Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$51.01	-$9.80	5.50%	0.00%	0.0%
2024A	-$38.11	-$9.30	36.70%	0.00%	0.0%
2023A	-$23.36	-$6.80	62.90%	0.00%	0.0%

PYC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$82,584M	0.7309	-0.4378	0.0505	10.6830	19.0019	18.0884	2.47%	2.44%	2.52%
Clinuvel Pharmaceuticals Limited (CUV)	$531M	0.0287	0.0000	0.0000	14.6518	0.0000	0.0000	0.48%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,065M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$2,134M	0.0548	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,263M	-1.3893	0.0000	-0.9102	0.0000	146.4083	1,630.5263	0.00%	0.00%	0.00%

PYC Directors

Name	Position	Start Date
Dr Rohan Hockings	Chief Executive Officer, Managing Director	30 Nov 2018
Mr Peter John Coleman	Non-Executive Chairman, Non-Executive Director	18 Nov 2025
Professor Ian Jeffrey Constable	Non-Executive Director	21 Sep 2025

PYC Therapeutics Limited (PYC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
24 Mar 2026	HOCKINGS, Rohan	Buy	Direct Shares	82,550	$1.210	$99,883.000
6 Mar 2026	HOCKINGS, Rohan	Issued	Direct Shares	80,010	$1.500	$120,015.000
6 Mar 2026	CONSTABLE, Ian	Issued	Indirect Shares	123,000	$1.500	$184,500.000

See all changes in directors' interest & trades for PYC Therapeutics Limited (PYC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PYC Management

Name	Position
Jonathan Riley	Joint Company Secretary
Stephen Ledger	Joint Company Secretary

PYC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in PYC Therapeutics Limited (PYC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
186,726,741 (32.01%)	Australian Land Pty Ltd

PYC Calendar of Events

Date	Event
22 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us